The United Kingdom’s National Institute for Health and Care Excellence (NICE), which provides the UK’s National Health Service with guidance on appropriate use of treatments, rejected new indications for second-line lenalidomide and second-line carfilzomib.
Lenalidomide is approved in the United Kingdom as a third-line treatment. The NICE committee determined that using lenalidomide earlier in the treatment course was not cost-effective, compared with other treatments such as melphalan.
NICE also rejected carfilzomib in combination with lenalidomide and dexamethasone or dexamethasone alone in patients with MM who have received at least one prior therapy, based on uncertainties in clinical and cost-effectiveness results. Committee members also could not agree on a cost-effectiveness estimate.
Source: Fierce Pharma, November 14, 2016.